Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 12/20 | 1.00 |
| ▸ | GSK3B | P49841 | 9/20 | 1.00 |
| ▸ | HTT | P42858 | 4/20 | 0.69 |
| ▸ | ROCK1 | Q13464 | 11/20 | 0.68 |
| ▸ | PRKACA | P17612 | 7/20 | 0.68 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1901013 | 0.82 | HTT (1.00) | RPS6KB1GSK3BHTTROCK1PRKACA | |
| Gw549034X SCHEMBL1900661 | 0.81 | RPS6KA5 (1.00) | RPS6KB1GSK3BHTTROCK1PRKACA | |
| SCHEMBL1900429 | 0.81 | RPS6KB1 (1.00) | RPS6KB1GSK3BHTTROCK1PRKACA | |
| SCHEMBL4717863 | 0.81 | RPS6KA5 (1.00) | RPS6KB1GSK3BHTTROCK1RPS6KA5 | |
| SCHEMBL6401508 | 0.80 | HTT (0.79) | RPS6KB1GSK3BHTTROCK1PRKACA | |
| SCHEMBL6406327 | 0.80 | HTT (1.00) | RPS6KB1GSK3BHTTROCK1PRKACA | |
| SCHEMBL1903910 | 0.79 | RPS6KB1 (1.00) | RPS6KB1GSK3BHTTROCK1PRKACA | |
| SCHEMBL1899581 | 0.79 | HTT (0.77) | RPS6KB1GSK3BHTTROCK1PRKACA | |
| SCHEMBL1899584 | 0.79 | RPS6KB1 (0.81) | RPS6KB1GSK3BHTTROCK1PRKACA | |
| SCHEMBL1907407 | 0.79 | HTT (0.93) | RPS6KB1GSK3BHTTROCK1PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2322521-B1 | Heteroaryl compounds useful as inhibitors of GSK-3 | VERTEX PHARMA (US) | 2013-09-04 | — | — | EP | claimed |
| EP-2322521-A1 | Heteroaryl compounds useful as inhibitors of GSK-3 | Vertex Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | claimed |
| JP-4656838-B2 | — | — | 2011-03-23 | — | — | JP | claimed |
| US-20070270420-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | claimed |
| JP-2005526028-A | — | — | 2005-09-02 | — | — | JP | claimed |
| EP-1472245-A2 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | Vertex Pharmaceuticals Incorporated (US) | 2004-11-03 | — | — | EP | claimed |
| US-20040034037-A1 | Heteroaryl compounds useful as inhibitors of GSK-3 | VERTEX PHARMACEUTICALS, INCORPORATED | 2004-02-19 | — | — | US | claimed |
| WO-2003066629-A2 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-08-14 | — | — | WO | claimed |
| EP-2322521-B1 | Heteroaryl compounds useful as inhibitors of GSK-3 | VERTEX PHARMA (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2322521-A1 | Heteroaryl compounds useful as inhibitors of GSK-3 | Vertex Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20070270420-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
| US-20070270420-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
| US-20070270420-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
| US-20050153978-A1 | Medicaments | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
| EP-1487441-A2 | BENZIMIDAZOLES AND THEIR USE AS MITOGEN-ACTIVATED- AND RHO-KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | disclosed |
| EP-1472245-A2 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | Vertex Pharmaceuticals Incorporated (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003080125-A2 | BENZIMIDAZOLES AND THEIR USE AS MITOGEN-ACTIVATED- AND RHO-KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
| WO-2003066629-A2 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270420-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | GSK3B, GSK3A, GSKIP | RPS6KB1 417/4885GSK3B 1/4885HTT 3199/4885 |
| US-20050153978-A1 | Medicaments | GRK1, ROCK1, GRK7 | RPS6KB1 63/4885GSK3B 403/4885HTT 4712/4885 |
| US-20040034037-A1 | Heteroaryl compounds useful as inhibitors of GSK-3 | GSK3B, GSK3A, GSKIP | RPS6KB1 417/4885GSK3B 1/4885HTT 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.